BioSpace News Archive

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. ET to provide a corporate update and results for the first quarter of 2022.

Medicenna Therapeutics Corp. announced that Dr. Fahar Merchant, President and CEO and Elizabeth Williams, CFO of Medicenna, will attend the conference and present a corporate overview at the 2022 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place from May 2 – May 3, 2022.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has kicked off the first production run of the second quarter for its recombinant spider silk.

Anavex Life Sciences Corp. announced presentations of Psychometric Evaluation of the Rett Syndrome Behaviour Questionnaire and Burden of Illness study in Rett syndrome by the respective working groups, at the IRSF Rett Syndrome Scientific Meeting, taking place in Nashville, TN, April 26–27, 2022.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), and Cend Therapeutics, Inc. (“Cend”), today announced that the companies have entered into a definitive merger agreement under which Cend will merge with a wholly owned subsidiary of Caladrius in an all-stock approximate “merger of equals” transaction unanimously approved by the Boards of Directors of each company.

Rise in use of augmented reality in the healthcare sector for various activities such as surgical simulation, diagnostic imaging, patient care management, and rehabilitation is boosting the sales opportunities in the global AR in healthcare market.

Albany NY, United States: Immune repertoire is the sum of T cell receptors and B cell receptors that make an organism’s adaptive immune system.

Ipsen, a global specialty-driven biopharmaceutical group, publishes its sales performance for the first quarter of 2022.

Basilea Pharmaceutica Ltd. announced that it has entered into a licensing agreement with the U.S.-based company, Fox Chase Chemical Diversity Center, Inc., for a preclinical program on novel first-in-class broad spectrum antifungals with activity against difficult-to-treat mold infections.

Spexis AG announced that its shareholders approved all proposals of the Board of Directors at the 25th Annual General Meeting with a significant majority.